Getting the front-loaded payoff

The broad potential of its lead compound to work with marketed antibiotics allowed Novexel S.A. to sell itself to AstraZeneca plc in a front-loaded deal last week - an increasingly rare feat for a company in mid-stage development.

The driver was NXL104, a beta lactamase inhibitor that allows established antibiotics to avoid bacterial resistance...